Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market

Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market


January 1, 2012
114 Pages - SKU: XGBR6744097
License type:
Online Download      US $3,500.00
Global Site License      US $10,500.00
Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market

Summary

GBI Research’s new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research has found that the global hepatitis market is one of the fast growing markets of the pharmaceutical industry. The approval of potential new drugs and combinational therapies with significant efficacy, safety and resistance profiles will fuel the rapid uptake of drugs in the near future. Limitations of the current standard care therapy for hepatitis include high incidence of adverse events, long duration of treatment, suboptimal patient compliance and the lack of efficacy in specific genotypes. This has increased interest in developing novel products able to potentially counter this unmet need.

Scope
  • Annualized market data for the hepatitis market from 2002 to 2010, forecast forward to 2017.
  • Analysis of the leading segments, including hepatitis A, hepatitis B and hepatitis C.
  • Analysis of the hepatitis market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various Phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
  • Key M&A activities, licensing agreements that have taken place between 2009 and mid-2011 in the global hepatitis market.
Reasons to buy
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.


Additional Information

GBI Research’s new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Hepatitis Market is Forecast to Show High Growth

The global hepatitis therapeutics and vaccines market generated approximately $4.7 billion in 2010. The market is anticipated to reach revenues of approximately $8.6 billion by 2017, growing at a Compound Annual Growth Rate of 9% between 2010 and 2017. From 2002 to 2010, the market grew at a CAGR of 3.8%.

Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2002-2017

Source: GBI Research, Annual reports

The hepatitis C market is expected to grow at a high rate during the forecast period whereas the hepatitis B market will witness low growth.

The target patient base of the hepatitis market includes newly infected or diagnosed hepatitis patients, non-responders and patients who have discontinued treatment. As a result, there is a huge unmet need in the market. The high cost of therapy has also proved a major concern.

The current hepatitis C pipeline does offer some promising novel products, and as a result the overall growth of the global hepatitis market is expected to show a moderate increase in the future.

The global hepatitis vaccines market is expected to increase by 2017. It is expected to grow at a higher rate between 2010 and 2017 than between 2002 and 2010. This can be primarily attributed to the introduction of novel vaccines in the market, such as Heplisav and spi-VEC among others.

Hepatitis Pipeline Portfolio is Dominated by Late-Stage Pipeline Candidates

Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011

Source: GBI Research’s Internal Database, company websites, ClinicalTrials.gov

The current hepatitis pipeline contains 237 projects across the different developmental stages. Hepatitis B and C currently account for more than two-thirds of the total hepatitis market and are the key therapy areas of focus in the current pipeline, of which they account for approximately 98%. More than 50% of the projects for hepatitis B and hepatitis C are in the early stages of research, which suggests that the market can expect novel drugs in the future.

The hepatitis C therapeutics pipeline has four molecules in Phase III, and the introduction of novel therapies will be a driver for the market. Products such as boceprevir, zalbin, telaprevir and RG7128 are already in the clinical development stage or approved by FDA, and their launch will reinforce the market growth.

The hepatitis B pipeline has 10 molecules in Phase III but most are combination therapies. Phase II is also dominated by combination therapies. The pipeline for hepatitis B lacks novel drugs and is therefore weak. The pipeline portfolio for hepatitis A is also weak, with four programs in various developmental stages. The high growth of the hepatitis C therapeutics market during the forecast period will support the global hepatitis market as a whole.

Large Number of Strategic Consolidations will Support Market Growth

Between 2009 and mid-2011, the hepatitis sector witnessed numerous strategic consolidations which are expected to result in high growth in the near future. There have been increasing numbers of licensing agreements for drugs in the hepatitis C pipeline portfolio, primarily due to the market’s high growth potential. The hepatitis C market also has the highest number of molecules in the pipeline portfolio, indicating a strong future. This will facilitate more Mergers and Acquisitions (M&As) and licensing agreements.

A total of 17 major licensing deals took place between 2010 and mid-2011 in the hepatitis market, including in the field of hepatitis B and hepatitis C therapeutics. Hepatitis B therapeutics accounted for 61% of deals in licensing agreements. This is the main area of focus for companies active in the hepatitis therapeutics market due to the potential for growth. Approximately 39% of deals were for hepatitis C therapeutics.

More Hepatitis reports by GBI Research

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape by GBI Research
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial LandscapeSummaryGBI Research, has released ...
Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth by GBI Research
Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive GrowthSummaryThe leading business intelligence provider GBI Research has released ...
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy by GBI Research
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination TherapySummaryGBI Research, the ...
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets by GBI Research
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets Summary GBI Research has ...
See all reports like this >>